Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444279 | 0.87 | HTR2C (0.54) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL4443781 | 0.80 | HDAC2 (0.54) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7972021 | 0.78 | F10 (0.56) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7392566 | 0.78 | F10 (0.56) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7989809 | 0.77 | PRSS1 (0.57) | — | |
| SCHEMBL7425136 | 0.77 | PRSS1 (0.57) | — | |
| SCHEMBL7986197 | 0.77 | PRSS1 (0.57) | — | |
| SCHEMBL7983619 | 0.76 | F10 (0.57) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL7972008 | 0.75 | F10 (0.62) | SMN1; SMN2DRD2DRD3HRH3LMNA | |
| Hydrochloric Acid SCHEMBL5092926 | 0.74 | LOX (0.55) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008127364-A2 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | NPC1 211/4885RAB9A 2589/4885SMN1; SMN2 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.